Drug intelligence / Profile preview

Coquelusedal Enfant

Development stage: Unknown
Lead developer: Laboratoires Élerté
Modality: Small Molecules
Administration: Rectal

Overview

Coquelusedal Enfant is a herbal medicinal product developed by Laboratoire ELERTE, indicated as an adjunctive treatment for mild acute bronchial disorders in children. Administered rectally as a suppository, it contains hydroalcoholic extracts of *Grindelia robusta* and *Gelsemium sempervirens*. These botanical components are traditionally recognized for their antitussive and antispasmodic activities, helping to manage cough symptoms associated with common ear, nose, and throat (ENT) and respiratory conditions. The product is approved and marketed in France for pediatric use, specifically for children aged 30 months to 15 years.

Brand names: Coquelusedal Enfant
Other names: Coquelusedal

Beyond the preview

Go deeper on Coquelusedal Enfant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coquelusedal Enfant.

Explore the full profile